CL2011003079A1 - Compuestos derivados aromaticos o heteroaromaticos de heterociclos nitrogenados de oxima, agonista de receptor gpr119; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades mediadas por la modulacion de dicha actividad, como obecidad y diabetes. - Google Patents
Compuestos derivados aromaticos o heteroaromaticos de heterociclos nitrogenados de oxima, agonista de receptor gpr119; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades mediadas por la modulacion de dicha actividad, como obecidad y diabetes.Info
- Publication number
- CL2011003079A1 CL2011003079A1 CL2011003079A CL2011003079A CL2011003079A1 CL 2011003079 A1 CL2011003079 A1 CL 2011003079A1 CL 2011003079 A CL2011003079 A CL 2011003079A CL 2011003079 A CL2011003079 A CL 2011003079A CL 2011003079 A1 CL2011003079 A1 CL 2011003079A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- modulation
- activity
- pharmaceutical composition
- oxime
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Compuestos derivados de piperidina; composición farmacéutica; y uso para tratar enfermedades o afecciones que están mediadas por la modulación de la actividad de la enzima gpr119.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22013309P | 2009-06-24 | 2009-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011003079A1 true CL2011003079A1 (es) | 2012-06-01 |
Family
ID=42557541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011003079A CL2011003079A1 (es) | 2009-06-24 | 2011-12-05 | Compuestos derivados aromaticos o heteroaromaticos de heterociclos nitrogenados de oxima, agonista de receptor gpr119; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades mediadas por la modulacion de dicha actividad, como obecidad y diabetes. |
Country Status (18)
Country | Link |
---|---|
US (1) | US8293729B2 (es) |
EP (1) | EP2445878A1 (es) |
JP (1) | JP5467151B2 (es) |
KR (1) | KR20120046188A (es) |
CN (1) | CN102803214A (es) |
AR (1) | AR077215A1 (es) |
AU (1) | AU2010264720A1 (es) |
BR (1) | BR112012000831A2 (es) |
CA (1) | CA2766696A1 (es) |
CL (1) | CL2011003079A1 (es) |
EA (1) | EA201200046A1 (es) |
IL (1) | IL216388A0 (es) |
MX (1) | MX2011013648A (es) |
NZ (1) | NZ596445A (es) |
TW (1) | TW201111361A (es) |
UY (1) | UY32731A (es) |
WO (1) | WO2010149684A1 (es) |
ZA (1) | ZA201108292B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077214A1 (es) | 2009-06-24 | 2011-08-10 | Neurocrine Biosciences Inc | Heterociclos nitrogenados y composiciones farmaceuticas que los contienen |
CA2766696A1 (en) | 2009-06-24 | 2010-12-29 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
KR20130101524A (ko) | 2010-09-01 | 2013-09-13 | 아레나 파마슈티칼스, 인크. | 5-ht2c 아고니스트의 비-흡습성 염 |
EP2611781A1 (en) | 2010-09-01 | 2013-07-10 | Arena Pharmaceuticals, Inc. | Fast-dissolve dosage forms of 5-ht2c agonists |
AU2011296003B2 (en) | 2010-09-01 | 2015-11-12 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-HT2C agonist useful for weight management |
WO2012030938A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Salts of lorcaserin with optically active acids |
UY33805A (es) | 2010-12-17 | 2012-07-31 | Boehringer Ingelheim Int | ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?. |
US8778926B2 (en) | 2011-01-21 | 2014-07-15 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
EP2686312B1 (en) | 2011-03-14 | 2016-08-31 | Boehringer Ingelheim International GmbH | N-cyclopropyl-n-piperidinylbenzamides as gpr119 modulators |
WO2012168315A1 (en) | 2011-06-09 | 2012-12-13 | Boehringer Ingelheim International Gmbh | Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders |
US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
RU2733951C9 (ru) * | 2015-08-06 | 2020-12-22 | Убе Индастриз, Лтд. | Замещенные производные гуанидина |
LT3564230T (lt) | 2016-12-28 | 2022-04-11 | Ube Industries, Ltd. | Pakeistas guanidino junginys |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3970697A (en) * | 1996-08-15 | 1998-03-06 | Du Pont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as iib/iiia antagonists |
US6329418B1 (en) | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
US20030017528A1 (en) | 1998-11-20 | 2003-01-23 | Ruoping Chen | Human orphan G protein-coupled receptors |
US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
WO2002102783A1 (en) | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
ATE552253T1 (de) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
US7083933B1 (en) | 2003-05-09 | 2006-08-01 | Prosidion Limited | Methods for identification of modulators of OSGPR116 activity |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
JP4958560B2 (ja) | 2003-12-24 | 2012-06-20 | プロシディオン・リミテッド | Gpcr受容体作動薬としてのヘテロ環誘導体 |
WO2005097129A2 (en) * | 2004-04-05 | 2005-10-20 | Takeda Pharmaceutical Company Limited | 6-azaindole compound |
EP1741702A1 (en) * | 2004-04-28 | 2007-01-10 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
US20090036434A1 (en) | 2004-06-04 | 2009-02-05 | Arena Pharmaceuticals, Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
WO2006067532A1 (en) | 2004-12-24 | 2006-06-29 | Prosidion Ltd | G-protein coupled receptor agonists |
NZ556017A (en) | 2004-12-24 | 2009-10-30 | Prosidion Ltd | G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
JP2008527030A (ja) | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | 炎症の治療に有用なインドール類 |
EP1844013A1 (en) | 2005-01-19 | 2007-10-17 | Biolipox AB | Indoles useful in the treatment of inflammation |
WO2006077365A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflammation |
EP1907384A2 (en) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
MX2007016545A (es) | 2005-06-30 | 2008-02-21 | Prosidion Ltd | Agonistas del receptor acoplado a la proteina g. |
EP1907383A1 (en) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
JP2008545009A (ja) | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Gpcrアゴニスト |
GEP20104966B (en) | 2005-09-16 | 2010-04-26 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
US7763623B2 (en) * | 2006-01-20 | 2010-07-27 | Schering Corporation | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia |
KR20090052301A (ko) | 2006-03-16 | 2009-05-25 | 노파르티스 아게 | 특히 흑색종의 치료를 위한 헤테로고리형 유기 화합물 |
CA2646676A1 (en) | 2006-04-06 | 2007-10-18 | Prosidion Limited | Heterocyclic gpcr agonists |
GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
NZ571110A (en) | 2006-04-11 | 2011-03-31 | Arena Pharm Inc | Methods of using GPR119 receptor to identify Glucose-dependent Insulinotropic Peptide (GIP) secretagogue compounds useful for increasing bone mass in an individual |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
GB0610746D0 (en) | 2006-06-01 | 2006-07-12 | Prosidion Ltd | Method of treatment |
TW200811140A (en) | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
TW200811147A (en) | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
JP2009543805A (ja) | 2006-07-13 | 2009-12-10 | スミスクライン ビーチャム コーポレーション | インドリン誘導体及びgpr119作動物質 |
WO2008009924A2 (en) | 2006-07-18 | 2008-01-24 | Biolipox Ab | Indoles useful in the treatment of inflammation |
CA2660699A1 (en) | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyridine compounds for treating gpr119 related disorders |
EP2325182A1 (en) | 2006-12-06 | 2011-05-25 | Glaxosmithkline LLC | Bicyclic compounds and use as antidiabetics |
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
SI2114933T1 (sl) | 2007-01-04 | 2012-01-31 | Prosidion Ltd Windrush Court | Piperidinski gpcr-agonisti |
AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
BRPI0806312A2 (pt) | 2007-01-04 | 2011-09-06 | Prosidion Ltd | agonistas cgpr piperidina |
JP4328820B2 (ja) * | 2007-01-10 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
PE20081791A1 (es) | 2007-02-28 | 2009-02-07 | Eisai Randd Man Co Ltd | Dos derivados ciclicos de oxomorfolina |
US20100120807A1 (en) | 2007-03-08 | 2010-05-13 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
RU2009139931A (ru) | 2007-03-29 | 2011-05-10 | Асубио Фарма Ко., Лтд. (Jp) | Производные индола, обладающие ингибирующей активностью в отношении сpla2, и способы их получения |
ES2388315T3 (es) | 2007-05-04 | 2012-10-11 | Bristol-Myers Squibb Company | Agonistas [6,5]-bicíclicos de receptores GPR119 acoplados a la proteína G |
PE20090222A1 (es) | 2007-05-04 | 2009-03-27 | Bristol Myers Squibb Co | Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119 |
ATE540945T1 (de) | 2007-07-17 | 2012-01-15 | Bristol Myers Squibb Co | Verfahren zur modulation des gpr119-g- proteingekoppelten rezeptors und ausgewählte verbindungen |
KR20100033419A (ko) | 2007-07-19 | 2010-03-29 | 메타볼렉스, 인코포레이티드 | 당뇨병 및 대사 장애의 치료를 위한 rup3 또는 gpr119 수용체의 작용제로서 n-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체 |
WO2009034388A1 (en) | 2007-09-10 | 2009-03-19 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
ES2499018T3 (es) | 2007-09-20 | 2014-09-26 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de GPR119 |
CN101896481B (zh) | 2007-10-16 | 2014-04-30 | 第一三共株式会社 | 嘧啶基二氢吲哚化合物 |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
KR20100075643A (ko) | 2007-10-22 | 2010-07-02 | 쉐링 코포레이션 | 비사이클릭 헤테로사이클 유도체 및 gpr119의 활성의 조절인자로서의 이의 용도 |
EP2224928A4 (en) | 2007-12-06 | 2012-02-15 | Glaxosmithkline Llc | NOVEL INHIBITORS OF SEH AND THEIR USE |
EA201001332A1 (ru) | 2008-02-22 | 2011-04-29 | Айрм Ллк | Соединения и композиции в качестве модуляторов активности gpr119 |
WO2009105717A1 (en) | 2008-02-22 | 2009-08-27 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2009106565A1 (en) | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Agonists of gpr119 |
WO2009106561A1 (en) | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Pyrazine compounds for treating gpr119 related disorders |
WO2009117421A2 (en) * | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
CA2720049A1 (en) | 2008-03-31 | 2009-10-08 | Zenyaku Kogyo Kabushikikaisha | Pyrimidine derivative having cell protecting effect and uses thereof |
US20090270404A1 (en) | 2008-03-31 | 2009-10-29 | Metabolex, Inc. | Oxymethylene aryl compounds and uses thereof |
CN102056900A (zh) | 2008-04-07 | 2011-05-11 | Irm责任有限公司 | 作为gpr119活性调节剂的化合物和组合物 |
WO2009125434A2 (en) | 2008-04-07 | 2009-10-15 | Cadila Healthcare Limited | Oxime derivatives |
EP2297129B1 (en) | 2008-04-14 | 2013-07-24 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
WO2009150144A1 (en) | 2008-06-10 | 2009-12-17 | Inovacia Ab | New gpr119modulators |
WO2010008739A2 (en) | 2008-06-20 | 2010-01-21 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
GB0812648D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
GB0812642D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
ATE557024T1 (de) | 2008-07-10 | 2012-05-15 | Prosidion Ltd | Piperidinverbindungen als gpcr-agonisten |
GB0812649D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
PE20110329A1 (es) | 2008-07-10 | 2011-06-03 | Prosidion Ltd | Agonistas del receptor acoplado a la proteina g piperidinilo |
GB0812641D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
BRPI0915867A2 (pt) | 2008-07-11 | 2017-06-20 | Irm Llc | 4-fenoximetilpiperidinas como moduladores de atividade de gpr119 |
TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
US8822480B2 (en) | 2008-07-16 | 2014-09-02 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and use thereof as GPR119 modulators |
EP2320910A4 (en) | 2008-07-30 | 2012-12-19 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS AND ITS USE |
JPWO2010013849A1 (ja) | 2008-08-01 | 2012-01-12 | 日本ケミファ株式会社 | Gpr119作動薬 |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2010059384A1 (en) | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
US20100113480A1 (en) | 2008-10-30 | 2010-05-06 | Michael Reuman | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
EP2382204B1 (en) | 2008-12-23 | 2018-07-11 | Merck Sharp & Dohme Corp. | Pyrimidine derivatives as gpcr modulators for use in the treatment of obesity and diabetes |
CA2747809A1 (en) | 2008-12-23 | 2010-07-01 | Joel M. Harris | Bicyclic heterocycle derivatives and methods of use thereof |
WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
WO2010084512A1 (en) | 2008-12-24 | 2010-07-29 | Cadila Healthcare Limited | Novel oxime derivatives |
WO2010074271A1 (ja) | 2008-12-26 | 2010-07-01 | 武田薬品工業株式会社 | 糖尿病治療剤 |
TW201031668A (en) | 2009-01-22 | 2010-09-01 | Mitsubishi Tanabe Pharma Corp | Novel pyrrolo[2,3-d] pyrimidine compound |
WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
JP5657518B2 (ja) | 2009-02-18 | 2015-01-21 | 武田薬品工業株式会社 | 縮合複素環化合物 |
GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
US20120095028A1 (en) | 2009-03-20 | 2012-04-19 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
AR076024A1 (es) | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
EP2414348B1 (en) | 2009-04-03 | 2013-11-20 | Merck Sharp & Dohme Corp. | Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders |
JP2012136439A (ja) | 2009-04-24 | 2012-07-19 | Nippon Chemiphar Co Ltd | ジアザスピロアルカン誘導体 |
WO2010128414A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
EP2427450A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
US20110015215A1 (en) | 2009-05-20 | 2011-01-20 | Paul Deghetto | Crystalline forms of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester |
WO2010135506A1 (en) | 2009-05-20 | 2010-11-25 | Janssen Pharmaceutica Nv | Process for the preparation of 4- [6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino) -5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester |
EP2438051A1 (en) | 2009-06-05 | 2012-04-11 | Pfizer Inc. | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
AR077214A1 (es) | 2009-06-24 | 2011-08-10 | Neurocrine Biosciences Inc | Heterociclos nitrogenados y composiciones farmaceuticas que los contienen |
CA2766696A1 (en) | 2009-06-24 | 2010-12-29 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
EP2566864B1 (en) | 2010-05-07 | 2014-09-03 | Boehringer Ingelheim International GmbH | Pyridazinones as gpr119 agonists |
-
2010
- 2010-06-23 CA CA2766696A patent/CA2766696A1/en not_active Abandoned
- 2010-06-23 JP JP2012516706A patent/JP5467151B2/ja active Active
- 2010-06-23 NZ NZ596445A patent/NZ596445A/xx not_active IP Right Cessation
- 2010-06-23 BR BR112012000831A patent/BR112012000831A2/pt not_active IP Right Cessation
- 2010-06-23 EA EA201200046A patent/EA201200046A1/xx unknown
- 2010-06-23 AR ARP100102227A patent/AR077215A1/es unknown
- 2010-06-23 MX MX2011013648A patent/MX2011013648A/es not_active Application Discontinuation
- 2010-06-23 KR KR1020127001636A patent/KR20120046188A/ko not_active Application Discontinuation
- 2010-06-23 TW TW099120493A patent/TW201111361A/zh unknown
- 2010-06-23 WO PCT/EP2010/058873 patent/WO2010149684A1/en active Application Filing
- 2010-06-23 US US12/821,231 patent/US8293729B2/en active Active
- 2010-06-23 EP EP10728189A patent/EP2445878A1/en not_active Withdrawn
- 2010-06-23 AU AU2010264720A patent/AU2010264720A1/en not_active Abandoned
- 2010-06-23 CN CN2010800283693A patent/CN102803214A/zh active Pending
- 2010-06-24 UY UY0001032731A patent/UY32731A/es not_active Application Discontinuation
-
2011
- 2011-11-11 ZA ZA2011/08292A patent/ZA201108292B/en unknown
- 2011-11-16 IL IL216388A patent/IL216388A0/en unknown
- 2011-12-05 CL CL2011003079A patent/CL2011003079A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2012530757A (ja) | 2012-12-06 |
UY32731A (es) | 2011-01-31 |
US20110166116A1 (en) | 2011-07-07 |
NZ596445A (en) | 2013-04-26 |
JP5467151B2 (ja) | 2014-04-09 |
BR112012000831A2 (pt) | 2019-09-24 |
US8293729B2 (en) | 2012-10-23 |
EA201200046A1 (ru) | 2012-08-30 |
CA2766696A1 (en) | 2010-12-29 |
MX2011013648A (es) | 2012-03-06 |
TW201111361A (en) | 2011-04-01 |
ZA201108292B (en) | 2012-07-25 |
CN102803214A (zh) | 2012-11-28 |
IL216388A0 (en) | 2012-01-31 |
KR20120046188A (ko) | 2012-05-09 |
AU2010264720A1 (en) | 2011-12-08 |
EP2445878A1 (en) | 2012-05-02 |
WO2010149684A1 (en) | 2010-12-29 |
AR077215A1 (es) | 2011-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011003079A1 (es) | Compuestos derivados aromaticos o heteroaromaticos de heterociclos nitrogenados de oxima, agonista de receptor gpr119; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades mediadas por la modulacion de dicha actividad, como obecidad y diabetes. | |
BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
CL2010001496A1 (es) | Compuestos derivados de (piridin-o pirimidin-)piperidina, agonistas de gpr119; composicion farmaceutica; y su uso para el tratamiento de la diabetes de tipo i, diabetes de tipo ii y enfermedades relacionadas tales como sindrome metabolico, dislipidemia y resistencia a la insulina. | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
ECSP10010042A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
BR112012008004A2 (pt) | compostos e composições como moduladores da atividade de gpr119 | |
CL2007002348A1 (es) | Compuestos heterociclicos, moduladores de la actividad de la estearoil-coa-desaturasa; composicion farmaceutica, util para el tratamiento de enfermedades tales como diabetes, dislipidemias, obesidad, anorexia y acne. | |
BR112012007747A2 (pt) | Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos | |
UA111579C2 (uk) | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ | |
CL2011001497A1 (es) | Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico. | |
CR20110103A (es) | Heteroarilos sustituidos | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
NO20084490L (no) | Nye forbindelser | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
CL2007003341A1 (es) | Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras. | |
CL2008003339A1 (es) | Compuestos derivados de pirimidin-2(1h)-ona, inhibidores de la 11b-hidroxiesteroide deshidrogenasa 1; composicion farmaceutica, util para el tratamiento de enfermedades tales como obesidad, hipertension e hiperlipidemia. | |
BRPI1013705A2 (pt) | compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica | |
DOP2012000006A (es) | Agonista de gpr119 | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
CL2012003681A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes. | |
UY30330A1 (es) | Nuevas formas polimorfas de (2s)-(4e)-n-metil-5-(3-(5-isopropoxipiridin)il)-4-penten-2-amina | |
CL2007002427A1 (es) | Compuestos derivados heterociclicos, inhibidores de metaloproteinasa de matriz; proceso de preparacion; composicion farmaceutica, util para el tratamiento o profilaxis de enfermedades inflamatorias o desordenes autoinmunes. | |
BRPI0811849A2 (pt) | Composto, composição farmacêutica, e, métodos para preparar o compost e para tratar doenças ou condições mediadas por ccr1 | |
CL2011000061A1 (es) | Compuestos derivados de tetrahidrocinolinas, inhibidores de la 11-beta-hsd1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, obesidad, trastornos de ingestion de comida o dislipidemia. |